Studies in models of NSCLC have shown that radiotherapy stimulates PD-L1 expression on KRAS-mutant tumor cells and synergizes with anti-PD-1 agent to induce regression of KRAS-driven genetically engineered mouse models of NSCLC [309]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.